Saint Herblain (France), March 21, 2019 – Valneva SE (“Valneva” or “the Company”), a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs, announced today the availability of its audited consolidated and statutory financial statements for the year ending December 31, 2018. The statements are available on the Company’s website https://www.valneva.com/en/investors-media/financial-reports.

Saint Herblain (France), February 21, 2019 – Valneva SE, a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs, reported today its full year unaudited consolidated financial results for the year ending December 31, 2018.

Valneva Announces New $59 Million IXIARO® Supply Contract with US Government

Saint Herblain (France), January 16, 2019 – Valneva SE (“Valneva” or “the Company”), a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs, announced today the signing of a new $59 million contract with the U.S. government Department of Defense for the supply of its Japanese encephalitis (JE) vaccine IXIARO®.

Valneva Announces its Intention to Delist from the Vienna Stock Exchange

Trading will be centralized on Euronext Paris

Saint-Herblain (France), January 7, 2019 – Valneva SE (“Valneva”), a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs, announced today that it intends to delist from the Vienna Stock Exchange (VSE) in order to focus on the best capital markets for life science companies and increase liquidity by centralizing trading on Euronext Paris.